Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.61 |
| ▸ | RXRB | P28702 | 3/20 | 0.61 |
| ▸ | DHODH | Q02127 | 6/20 | 0.56 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.55 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.55 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.55 |
| ▸ | BCL2 | P10415 | 1/20 | 0.53 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.52 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.51 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.50 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL505417 | 1.00 | RXRA (0.61) | RXRARXRBDHODHIGF2BP2SLC13A5 | |
| SCHEMBL5515377 | 0.89 | KMO (0.56) | RXRARXRBDHODHSLC13A5AURKA | |
| SCHEMBL3745780 | 0.84 | AURKA (0.67) | RXRAIGF2BP2AURKATPX2 | |
| SCHEMBL505538 | 0.83 | AURKA (0.69) | RXRARXRBIGF2BP2AURKATPX2 | |
| SCHEMBL5840598 | 0.83 | SLC13A5 (0.51) | DHODHSLC13A5FFAR1FFAR4MME | |
| SCHEMBL4900087 | 0.82 | CSNK2A2 (0.51) | RXRARXRBDHODHSLC6A7CSNK2A2 | |
| SCHEMBL496275 | 0.82 | MRGPRX4 (0.61) | AURKATPX2 | |
| SCHEMBL29459930 | 0.82 | MRGPRX4 (0.61) | AURKATPX2 | |
| SCHEMBL9138429 | 0.81 | FAAH (0.61) | AURKATPX2 | |
| SCHEMBL2744656 | 0.80 | ABL1 (0.51) | RXRARXRBDHODHIGF2BP2CSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | MAGI3, PYM1, MAG | RXRA 4515/4885RXRB 4498/4885DHODH 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.